1-[[5-bromo-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile
C26H19BrCl2N2O2 — CID 135281517
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[[5-bromo-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile
1-[[5-bromo-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile (PubChem CID 135281517) has the molecular formula C26H19BrCl2N2O2 and a molecular weight of 542.26 g/mol. Its IUPAC name is 1-[[5-bromo-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile.
Molecular Properties
| Compound Name | 1-[[5-bromo-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile |
|---|---|
| PubChem CID | 135281517 |
| Molecular Formula | C26H19BrCl2N2O2 |
| Molecular Weight | 542.26 g/mol |
| Exact Mass | 540.00 |
| IUPAC Name | 1-[[5-bromo-1-(4-chlorophenyl)-2-[(4-chlorophenyl)methyl]-3-oxoisoindol-1-yl]oxymethyl]cyclopropane-1-carbonitrile |
| SMILES | N#CC1(COC2(c3ccc(Cl)cc3)c3ccc(Br)cc3C(=O)N2Cc2ccc(Cl)cc2)CC1 |
| InChI | InChI=1S/C26H19BrCl2N2O2/c27-19-5-10-23-22(13-19)24(32)31(14-17-1-6-20(28)7-2-17)26(23,18-3-8-21(29)9-4-18)33-16-25(15-30)11-12-25/h1-10,13H,11-12,14,16H2 |
| InChIKey | RBDABFKKMMTPGH-UHFFFAOYSA-N |
| XLogP | 6.93 |
| TPSA | 53.33 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 542.26 |
| LogP ≤ 5 | 6.93 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 3 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 135281517 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.